Overview of Profound Medical's Offering
Profound Medical Corp. (NASDAQ: PROF) has made a significant announcement regarding its plans for a public offering of common shares. This offering aims not only at raising capital but also at enhancing the company's operational capabilities, especially in bringing advanced medical solutions to the market.
Objectives for Fund Utilization
The net proceeds from this offering are slated for critical initiatives including:
Commercialization of TULSA-PRO® Technology
Profound intends to allocate funds to further commercialize the TULSA-PRO® system in the United States. This advanced technology represents a crucial step in non-invasive medical treatments, combining real-time MRI and ultrasound techniques for precision in treating prostate conditions.
Global Development of Innovative Systems
Another major focus will be the continued development and commercialization of not only the TULSA-PRO® but also the Sonalleve® system. The latter is engineered for effective treatment of uterine fibroids and offers palliative care for patients suffering from bone metastases.
Collaboration with Underwriters
The offering will be conducted through a meticulous underwriting process with renowned financial entities, including Raymond James Ltd. and Lake Street Capital Markets stepping in as co-lead underwriters. This collaboration is key in shaping the experience and efficiency of the offering.
Market and Regulatory Considerations
Aside from internal preparations, Profound Medical's offering is influenced by several external factors including market conditions and regulatory approvals from the Toronto Stock Exchange and Nasdaq. The successful completion is expected to provide a robust platform for future growth and innovation.
Investor Information and Accessibility
Prospective investors interested in the offering will find detailed information readily available through the company's base shelf prospectus and the accompanying preliminary prospectus supplement. They are made accessible according to the relevant securities regulations, ensuring transparency throughout the process.
About Profound Medical Corp.
Profound Medical is a commercial-stage medical device company recognized for developing groundbreaking therapies that are both customizable and incision-free, targeted at ablation of diseased tissue. The impressive technology portfolio, including TULSA-PRO® and Sonalleve®, positions Profound as a leader in innovative medical solutions, aiming to improve patient outcomes while emphasizing safety and effectiveness.
Frequently Asked Questions
What is Profound Medical planning to do with the proceeds from the offering?
Profound Medical intends to use the proceeds primarily to further commercialize its TULSA-PRO® system and the Sonalleve® system, alongside general corporate purposes.
Who are the underwriters involved in the offering?
Raymond James Ltd. and Lake Street Capital Markets are acting as co-lead underwriters for the public offering.
What technologies are being focused on for commercialization?
The primary focus will be on the TULSA-PRO® system and the Sonalleve® platform, which offer innovative medical treatment solutions.
Will the offering be accessible outside Canada?
Yes, the offering is expected to take place in each province and territory of Canada and also in the United States.
How can investors obtain the prospectus related to the offering?
Investors can access the prospectus and any amendments free of charge through the company’s website and the proper regulatory filings on SEDAR+ and EDGAR.
